- Home
- GLUE vs WALD Comparison
GLUE vs WALD Comparison
Compare GLUE & WALD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLUE
- WALD
- Stock Information
- Founded
- GLUE 2019
- WALD 1988
- Country
- GLUE United States
- WALD United Kingdom
- Employees
- GLUE N/A
- WALD N/A
- Industry
- GLUE Biotechnology: Pharmaceutical Preparations
- WALD Package Goods/Cosmetics
- Sector
- GLUE Health Care
- WALD Consumer Discretionary
- Exchange
- GLUE Nasdaq
- WALD Nasdaq
- Market Cap
- GLUE 475.5M
- WALD 404.2M
- IPO Year
- GLUE 2021
- WALD 2021
- Fundamental
- Price
- GLUE $6.93
- WALD $3.65
- Analyst Decision
- GLUE Buy
- WALD Strong Buy
- Analyst Count
- GLUE 3
- WALD 4
- Target Price
- GLUE $12.67
- WALD $5.95
- AVG Volume (30 Days)
- GLUE 1.8M
- WALD 129.3K
- Earning Date
- GLUE 11-07-2024
- WALD 08-27-2024
- Dividend Yield
- GLUE N/A
- WALD N/A
- EPS Growth
- GLUE N/A
- WALD N/A
- EPS
- GLUE N/A
- WALD N/A
- Revenue
- GLUE $14,975,000.00
- WALD $240,382,000.00
- Revenue This Year
- GLUE N/A
- WALD $27.44
- Revenue Next Year
- GLUE N/A
- WALD $19.55
- P/E Ratio
- GLUE N/A
- WALD N/A
- Revenue Growth
- GLUE N/A
- WALD N/A
- 52 Week Low
- GLUE $3.21
- WALD $2.41
- 52 Week High
- GLUE $12.40
- WALD $11.72
- Technical
- Relative Strength Index (RSI)
- GLUE 39.61
- WALD 54.59
- Support Level
- GLUE $6.15
- WALD $3.50
- Resistance Level
- GLUE $7.95
- WALD $4.18
- Average True Range (ATR)
- GLUE 0.88
- WALD 0.23
- MACD
- GLUE -0.34
- WALD 0.03
- Stochastic Oscillator
- GLUE 17.18
- WALD 51.15
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform by developing, acquiring, accelerating, and scaling the next generation of conscious, purpose-driven brands. It is organized into two reportable segments namely Obagi Skincare and Milk Makeup.